Recombinant
RabMAb

Recombinant Anti-ErbB 2 antibody [EP1045Y] - BSA and Azide free (ab194979)

Overview

  • Product name

    Anti-ErbB 2 antibody [EP1045Y] - BSA and Azide free
    See all ErbB 2 primary antibodies
  • Description

    Rabbit monoclonal [EP1045Y] to ErbB 2 - BSA and Azide free
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, ICC/IF, IHC-P, IPmore details
    Unsuitable for: Flow Cyt
  • Species reactivity

    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to residues near the C terminus of Human ErbB 2 (UniProt P04626).

  • Positive control

    • SKBR-3 cell lysate; Human breast carcinoma tissue; SKBR cells
  • General notes

    Ab194979 is the carrier-free version of ab134182. This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.

    ab194979 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents.

    This product is a recombinant rabbit monoclonal antibody.

Properties

Applications

Our Abpromise guarantee covers the use of ab194979 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Detects a band of approximately 185 kDa (predicted molecular weight: 137 kDa).

Please check the parent abID, ab134182, for more information on dilutions.

ICC/IF Use at an assay dependent concentration.
IHC-P Use at an assay dependent concentration. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
IP Use at an assay dependent concentration.
  • Application notes
    Is unsuitable for Flow Cyt.
  • Target

    • Function

      Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding. Essential component of a neuregulin-receptor complex, although neuregulins do not interact with it alone. GP30 is a potential ligand for this receptor. Regulates outgrowth and stabilization of peripheral microtubules (MTs). Upon ERBB2 activation, the MEMO1-RHOA-DIAPH1 signaling pathway elicits the phosphorylation and thus the inhibition of GSK3B at cell membrane. This prevents the phosphorylation of APC and CLASP2, allowing its association with the cell membrane. In turn, membrane-bound APC allows the localization of MACF1 to the cell membrane, which is required for microtubule capture and stabilization.
      In the nucleus is involved in transcriptional regulation. Associates with the 5'-TCAAATTC-3' sequence in the PTGS2/COX-2 promoter and activates its transcription. Implicated in transcriptional activation of CDKN1A; the function involves STAT3 and SRC. Involved in the transcription of rRNA genes by RNA Pol I and enhances protein synthesis and cell growth.
    • Tissue specificity

      Expressed in a variety of tumor tissues including primary breast tumors and tumors from small bowel, esophagus, kidney and mouth.
    • Involvement in disease

      Hereditary diffuse gastric cancer
      Glioma
      Ovarian cancer
      Lung cancer
      Gastric cancer
      Chromosomal aberrations involving ERBB2 may be a cause gastric cancer. Deletions within 17q12 region producing fusion transcripts with CDK12, leading to CDK12-ERBB2 fusion leading to truncated CDK12 protein not in-frame with ERBB2.
    • Sequence similarities

      Belongs to the protein kinase superfamily. Tyr protein kinase family. EGF receptor subfamily.
      Contains 1 protein kinase domain.
    • Post-translational
      modifications

      Autophosphorylated. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit (Probable). Ligand-binding increases phosphorylation on tyrosine residues (PubMed:27134172). Signaling via SEMA4C promotes phosphorylation at Tyr-1248 (PubMed:17554007). Dephosphorylated by PTPN12 (PubMed:27134172).
    • Cellular localization

      Cytoplasm. Nucleus and Cell membrane. Cytoplasm, perinuclear region. Nucleus. Translocation to the nucleus requires endocytosis, probably endosomal sorting and is mediated by importin beta-1/KPNB1.
    • Information by UniProt
    • Database links

    • Alternative names

      • Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody
      • C erb B2/neu protein antibody
      • CD340 antibody
      • CD340 antigen antibody
      • Cerb B2/neu protein antibody
      • CerbB2 antibody
      • Erb b2 receptor tyrosine kinase 2 antibody
      • ErbB-2 proto-oncogene antibody
      • ERBB2 antibody
      • ERBB2_HUMAN antibody
      • HER 2 antibody
      • HER 2/NEU antibody
      • HER2 antibody
      • Herstatin antibody
      • Human epidermal growth factor receptor 2 antibody
      • Metastatic lymph node gene 19 protein antibody
      • MLN 19 antibody
      • MLN19 antibody
      • NEU antibody
      • NEU proto oncogene antibody
      • Neuro/glioblastoma derived oncogene homolog antibody
      • Neuroblastoma/glioblastoma derived oncogene homolog antibody
      • NGL antibody
      • p185erbB2 antibody
      • Proto-oncogene c-ErbB-2 antibody
      • Proto-oncogene Neu antibody
      • Receptor tyrosine-protein kinase erbB-2 antibody
      • TKR1 antibody
      • Tyrosine kinase type cell surface receptor HER2 antibody
      • Tyrosine kinase-type cell surface receptor HER2 antibody
      • V erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog) antibody
      • V erb b2 avian erythroblastic leukemia viral oncogene homolog 2 antibody
      • V erb b2 avian erythroblastic leukemia viral oncoprotein 2 antibody
      • V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) antibody
      • V erb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody
      • Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) antibody
      see all

    Images

    • Anti-ErbB 2 antibody [EP1045Y] - BSA and Azide free (ab194979) + SKBR-3 (human mammary gland adenocarcinoma) whole cell lysate at 15 µg

      Secondary
      Goat Anti-Rabbit IgG H&L (HRP) (ab97051)

      Predicted band size: 137 kDa
      Observed band size: 185 kDa
      why is the actual band size different from the predicted?


      Exposure time: 3 seconds


      Blocking buffer and concentration: 5% NFDM/TBST

      Diluting buffer and concentration: 5% NFDM/TBST

    • ab134182 (purified) at 1:30 dilution (2µg) immunoprecipitating ErbB 2 in HeLa whole cell lysate.
      Lane 1 (input): HeLa (Human cervix adenocarcinoma epithelial cell) whole cell lysate 10µg
      Lane 2 (+): ab134182 & HeLa whole cell lysate
      Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab134182 in HeLa whole cell lysate
      For western blotting, VeriBlot for IP Detection Reagent (HRP) (ab131366) was used for detection at 1:1000 dilution.
      Blocking and diluting buffer: 5% NFDM/TBST.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134182).

    • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of Human breast carcinoma tissue sections labeling ErbB 2 with Purified ab134182 at 1:1600 dilution (0.68 µg/ml). Heat mediated antigen retrieval was performed using Perform heat mediated antigen retrieval using ab93684 (Tris/EDTA buffer, pH 9.0). Tissue was counterstained with Hematoxylin. ImmunoHistoProbe one step HRP Polymer (ready to use) secondary antibody was used at 1:0 dilution. PBS instead of the primary antibody was used as the negative control.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134182).

    • Immunocytochemistry/Immunofluorescence analysis of SK-BR-3 (human mammary gland adenocarcinoma) labelling ErbB 2 with purified ab134182 at 1/125. Cells were fixed with 4% PFA and permeabilized with 0.1% Triton X-100. An Alexa Fluor® 488-conjugated goat anti-rabbit IgG (1/1000) was used as the secondary antibody (Ab150077). Nuclei counterstained with DAPI (blue).

      Control: PBS only

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134182).

    • Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labelling ErbB 2 with ab134182 at 1/100 dilution.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134182).

      Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

    • Immunofluorescent analysis of SKBR cells labelling ErbB 2 with ab134182 at 1/250 dilution.

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134182).

    • Equilibrium disassociation constant (KD)
      Learn more about KD

      Click here to learn more about KD

      This data was developed using the same antibody clone in a different buffer formulation containing PBS, BSA, glycerol, and sodium azide (ab134182).

    References

    This product has been referenced in:

    • Xie H & Wang H PRL-3 promotes breast cancer progression by downregulating p14ARF-mediated p53 expression. Oncol Lett 15:2795-2800 (2018). Read more (PubMed: 29435006) »
    • Chan KK  et al. Targeting estrogen receptor subtypes (ERa and ERß) with selective ER modulators in ovarian cancer. J Endocrinol 221:325-36 (2014). Human . Read more (PubMed: 24819599) »
    See all 7 Publications for this product

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab194979.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    Sign up